What is Sofie Biosciences?
Sofie Biosciences operates at the intersection of clinical diagnostics and therapeutic innovation. The company is dedicated to democratizing access to theranostics—a field that combines diagnostic imaging with targeted therapy—by mitigating the traditional cost and technical barriers associated with these sophisticated systems. Their comprehensive ecosystem includes a robust portfolio of imaging hardware, advanced radiochemistry platforms, and a specialized radiopharmacy network. By functioning as both a technology provider and a contract manufacturing organization, Sofie Biosciences enables healthcare providers to deliver more precise, biology-driven patient care, thereby establishing itself as a cornerstone of modern medical infrastructure.
How much funding has Sofie Biosciences raised?
Sofie Biosciences has raised a total of $55.6M across 6 funding rounds:
Series A
$5M
Grant
$1.5M
Private Equity
$3.7M
Series B
$16M
Debt
$2M
Series C
$27.4M
Series A (2013): $5M with participation from Cycad Group, Tata Industries, and MRM Capital
Grant (2014): $1.5M led by MRM Capital and Cycad Group
Private Equity (2016): $3.7M supported by Artiman Managment, LLC
Series B (2018): $16M featuring Mayor Richard Riordan
Debt (2020): $2M backed by PPP
Series C (2020): $27.4M with participation from Jubilant Pharma Limited
Key Investors in Sofie Biosciences
Cycad Group
Cycad Group is a technology-focused investment firm that targets high-impact sectors including healthcare and energy, leveraging cutting-edge innovation to address unmet market needs.
MRM Capital
MRM Capital Holdings provides strategic private equity and advisory services, focusing on long-term value enhancement for middle-market companies and undervalued assets.
Artiman Managment, LLC
Artiman Management LLC is an investment firm that supports innovative businesses leveraging technology to drive advancements in healthcare, diagnostics, and security.
What's next for Sofie Biosciences?
With a history of successful capital raises ranging from early-stage Series A backing to major enterprise-level financing, Sofie Biosciences is well-positioned for its next phase of market expansion. The recent funding context suggests a strategic focus on scaling its radiopharmacy network and accelerating the commercialization of its proprietary imaging systems. As the company matures, the emphasis will likely shift toward deepening its integration within global healthcare systems, enhancing its contract manufacturing capabilities, and expanding its pipeline of novel diagnostic agents. This trajectory indicates a clear intent to lead the transition toward personalized, theranostic-centered clinical workflows, ensuring long-term value creation for stakeholders and improved health outcomes for patients worldwide.
See full Sofie Biosciences company page
